Paying users zone. Data is hidden behind: .
Get 1-month access to Gilead Sciences Inc. for $15.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Gilead Sciences Inc. pages available today for free:
Analysis of Profitability Ratios
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Gilead Sciences Inc., profitability ratios
Based on: 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24).
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Gilead Sciences Inc.’s gross profit margin ratio deteriorated from 2017 to 2018 but then slightly improved from 2018 to 2019. |
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Gilead Sciences Inc.’s operating profit margin ratio deteriorated from 2017 to 2018 and from 2018 to 2019. |
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Gilead Sciences Inc.’s net profit margin ratio improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019. |
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Gilead Sciences Inc.’s ROE improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level. |
ROA | A profitability ratio calculated as net income divided by total assets. | Gilead Sciences Inc.’s ROA improved from 2017 to 2018 and from 2018 to 2019. |
Gross Profit Margin
Gilead Sciences Inc., gross profit margin calculation, comparison to benchmarks
Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Gross profit on product sales | ||||||
Product sales | ||||||
Profitability Ratio | ||||||
Gross profit margin1 | ||||||
Benchmarks | ||||||
Gross Profit Margin, Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. |
Based on: 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24).
1 2019 Calculation
Gross profit margin = 100 × Gross profit on product sales ÷ Product sales
= 100 × ÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Gilead Sciences Inc.’s gross profit margin ratio deteriorated from 2017 to 2018 but then slightly improved from 2018 to 2019. |
Operating Profit Margin
Gilead Sciences Inc., operating profit margin calculation, comparison to benchmarks
Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Income from operations | ||||||
Product sales | ||||||
Profitability Ratio | ||||||
Operating profit margin1 | ||||||
Benchmarks | ||||||
Operating Profit Margin, Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
Operating Profit Margin, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
Operating Profit Margin, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24).
1 2019 Calculation
Operating profit margin = 100 × Income from operations ÷ Product sales
= 100 × ÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Gilead Sciences Inc.’s operating profit margin ratio deteriorated from 2017 to 2018 and from 2018 to 2019. |
Net Profit Margin
Gilead Sciences Inc., net profit margin calculation, comparison to benchmarks
Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net income attributable to Gilead | ||||||
Product sales | ||||||
Profitability Ratio | ||||||
Net profit margin1 | ||||||
Benchmarks | ||||||
Net Profit Margin, Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
Net Profit Margin, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
Net Profit Margin, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24).
1 2019 Calculation
Net profit margin = 100 × Net income attributable to Gilead ÷ Product sales
= 100 × ÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Gilead Sciences Inc.’s net profit margin ratio improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019. |
Return on Equity (ROE)
Gilead Sciences Inc., ROE calculation, comparison to benchmarks
Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net income attributable to Gilead | ||||||
Total Gilead stockholders’ equity | ||||||
Profitability Ratio | ||||||
ROE1 | ||||||
Benchmarks | ||||||
ROE, Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
ROE, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
ROE, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24).
1 2019 Calculation
ROE = 100 × Net income attributable to Gilead ÷ Total Gilead stockholders’ equity
= 100 × ÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Gilead Sciences Inc.’s ROE improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level. |
Return on Assets (ROA)
Gilead Sciences Inc., ROA calculation, comparison to benchmarks
Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net income attributable to Gilead | ||||||
Total assets | ||||||
Profitability Ratio | ||||||
ROA1 | ||||||
Benchmarks | ||||||
ROA, Competitors2 | ||||||
Abbott Laboratories | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Illumina Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Zoetis Inc. | ||||||
ROA, Sector | ||||||
Pharmaceuticals & Biotechnology | ||||||
ROA, Industry | ||||||
Health Care |
Based on: 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24).
1 2019 Calculation
ROA = 100 × Net income attributable to Gilead ÷ Total assets
= 100 × ÷ =
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROA | A profitability ratio calculated as net income divided by total assets. | Gilead Sciences Inc.’s ROA improved from 2017 to 2018 and from 2018 to 2019. |